
Keywords: MS; multiple sclerosis; DMT; disease modifying therapy; RRMS; relapsing-remitting MS; NEDA; no evidence of disease activity; N/E; new or enlarging; GdE; gadolinium enhancing; KP; knowledge program; EQ-5D; European Quality of Life 5-Dimensions; PS; Perform